Vivos therapeutics reports third quarter 2023 financial results and provides operational update

Operating expenses decreased 32% year over year and 19% sequentially as cost cutting measures take hold new strategic relationships, including u.s. nationwide distribution agreement with lincare, expected to add potentially significant new revenue opportunities management to host conference call today at 5:00 pm et littleton, colo., nov. 14, 2023 (globe newswire) -- vivos therapeutics, inc. (“vivos” or the “company'') (nasdaq: vvos), a medical technology company focused on developing innovative treatments for patients suffering from dentofacial abnormalities and/or mild-to-moderate obstructive sleep apnea (osa) and snoring in adults, today reported financial results and operating highlights for the third quarter and nine months ended september 30, 2023.
VVOS Ratings Summary
VVOS Quant Ranking